Literature DB >> 25497407

Mmp1a and Mmp1b are not functional orthologs to human MMP1 in cigarette smoke induced lung disease.

Phillip I Carver1, Vincent Anguiano1, Jeanine M D'Armiento1, Takayuki Shiomi2.   

Abstract

Matrix Metalloproteinase 1 (MMP1, collagenase-1) expression is implicated in a number of diseased states including emphysema and malignant tumors. The cigarette-smoke induced expression of this interstitial collegenase has been studied extensively and its inhibition proposed as a novel therapeutic treatment for tobacco related diseases such as chronic obstructive pulmonary disease (COPD) and lung cancer. However, a limitation in MMP1 research is the inability to take advantage of natural in vivo studies as most research has been performed in vitro or via animal models expressing human forms of the gene due to the lack of a rodent ortholog of MMP1. The present study examines the function of two possible mouse orthologs of human MMP1 known as Mmp1a and Mmp1b. Using genomic sequence analysis and expression analysis of these enzymes, the data demonstrate that neither MMP1a nor MMP1b behave in the same manner as human MMP1 in the presence of cigarette smoke. These findings establish that the two commonly proposed orthologs of MMP1, Mmp1a and Mmp1b, provide substantial limitations for use in examining MMP1 induced lung disease in mouse models of cigarette smoke emphysema.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Animal model; Gene expression regulation; Mice; Proteinase

Mesh:

Substances:

Year:  2014        PMID: 25497407      PMCID: PMC4308467          DOI: 10.1016/j.etp.2014.11.004

Source DB:  PubMed          Journal:  Exp Toxicol Pathol        ISSN: 0940-2993


  34 in total

Review 1.  New functions for the matrix metalloproteinases in cancer progression.

Authors:  Mikala Egeblad; Zena Werb
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

2.  ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis.

Authors:  V Lemaître; T K O'Byrne; A C Borczuk; Y Okada; A R Tall; J D'Armiento
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema.

Authors:  K Imai; S S Dalal; E S Chen; R Downey; L L Schulman; M Ginsburg; J D'Armiento
Journal:  Am J Respir Crit Care Med       Date:  2001-03       Impact factor: 21.405

4.  Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation.

Authors:  M Balbín; A Fueyo; V Knäuper; J M López; J Alvarez; L M Sánchez; V Quesada; J Bordallo; G Murphy; C López-Otín
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

5.  Disruption of the myocardial extracellular matrix leads to cardiac dysfunction.

Authors:  H E Kim; S S Dalal; E Young; M J Legato; M L Weisfeldt; J D'Armiento
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

6.  The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function.

Authors:  Ladina Joos; Jian-Qing He; Megan B Shepherdson; John E Connett; Nicholas R Anthonisen; Peter D Paré; Andrew J Sandford
Journal:  Hum Mol Genet       Date:  2002-03-01       Impact factor: 6.150

Review 7.  Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.

Authors:  Barbara Fingleton
Journal:  Expert Opin Ther Targets       Date:  2003-06       Impact factor: 6.902

Review 8.  MMP-1: the elder of the family.

Authors:  Annie Pardo; Moisés Selman
Journal:  Int J Biochem Cell Biol       Date:  2005-02       Impact factor: 5.085

9.  Extracellular regulated kinase/mitogen activated protein kinase is up-regulated in pulmonary emphysema and mediates matrix metalloproteinase-1 induction by cigarette smoke.

Authors:  Becky A Mercer; Natalia Kolesnikova; Joshua Sonett; Jeanine D'Armiento
Journal:  J Biol Chem       Date:  2004-02-05       Impact factor: 5.157

10.  The development of emphysema in cigarette smoke-exposed mice is strain dependent.

Authors:  Alexei Guerassimov; Yuma Hoshino; Yasutaka Takubo; Antony Turcotte; Midori Yamamoto; Heberto Ghezzo; Alexandra Triantafillopoulos; Kevin Whittaker; John R Hoidal; Manuel G Cosio
Journal:  Am J Respir Crit Care Med       Date:  2004-07-28       Impact factor: 21.405

View more
  5 in total

Review 1.  Collagenolytic matrix metalloproteinases in chronic obstructive lung disease and cancer.

Authors:  Denzel Woode; Takayuki Shiomi; Jeanine D'Armiento
Journal:  Cancers (Basel)       Date:  2015-02-05       Impact factor: 6.639

2.  Heterologous Matrix Metalloproteinase Gene Promoter Activity Allows In Vivo Real-time Imaging of Bleomycin-Induced Lung Fibrosis in Transiently Transgenized Mice.

Authors:  Fabio Franco Stellari; Francesca Ruscitti; Daniela Pompilio; Francesca Ravanetti; Giulia Tebaldi; Francesca Macchi; Andrea Elizabeth Verna; Gino Villetti; Gaetano Donofrio
Journal:  Front Immunol       Date:  2017-03-01       Impact factor: 7.561

3.  Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology.

Authors:  Ziqi Meng; Xinkui Liu; Jiarui Wu; Wei Zhou; Kaihuan Wang; Zhiwei Jing; Shuyu Liu; Mengwei Ni; Xiaomeng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-05-28       Impact factor: 2.629

4.  Screening the components of Saussurea involucrata for novel targets for the treatment of NSCLC using network pharmacology.

Authors:  Dongdong Zhang; Tieying Zhang; Yao Zhang; Zhongqing Li; He Li; Yueyang Zhang; Chenggong Liu; Zichao Han; Jin Li; Jianbo Zhu
Journal:  BMC Complement Med Ther       Date:  2022-02-28

5.  Exploring the mechanism of action of licorice in the treatment of COVID-19 through bioinformatics analysis and molecular dynamics simulation.

Authors:  Jun-Feng Cao; Yunli Gong; Mei Wu; Xingyu Yang; Li Xiong; Shengyan Chen; Zixuan Xiao; Yang Li; Lixin Zhang; Wang Zan; Xiao Zhang
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.